Diabetes Mellitus Type 2, Diabetic Macular Edema
Conditions
Keywords
Diffuse Diabetic Macular Edema, Intravitreal Bevacizumab, Anti-VEGF drugs
Brief summary
Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
Detailed description
A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up) pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein angiography was evaluated at months 1 and 3.
Interventions
Sponsors
Asociación para Evitar la Ceguera en México
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes * Macular edema involving the center of the macula demonstrated on OCT * Clear ocular media * Untreated patients * Older than 45 years * BCVA of the fellow eye at least 20/100
Exclusion criteria
* Renal diabetic disease, uncontrolled hypertension or stroke history * Other ocular disease * Ocular surgery excepting uncomplicated phacoemulsification * History of photocoagulation (panretinal or focal) * History of another intravitreal treatment (like triamcinolone)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA | — |
| Fluorescein Angiography | — |
| Optical Coherence Tomography | — |
Countries
Mexico
Outcome results
None listed